CSF Biomarkers May Distinguish MSA from Lewy-Body Alpha-Synucleinopathies Before the Onset of Debilitating Symptoms
In patients with autonomic failure, the combination of elevated neurofilament light and alpha-synuclein oligomers in the cerebrospinal fluid can distinguish between multiple system atrophy and Parkinson’s disease/dementia with Lewy bodies. Early diagnosis is critical for the development of treatment trials.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.